|
Aurobindo Pharma Limited has
registered a total income of Rs.5067 million
(Rs. 3271 million), EBITDA of Rs.958 million
(Rs.291 million) and PAT of Rs.546 million
(Rs.36 million) for the quarter ended September
30, 2006. |
|
During the quarter the total
income, EBITDA and PAT have shown a growth of
55%, 229% and 1417% respectively as compared to
the corresponding quarter of previous year. The
operating margin (EBITDA) and PAT have risen to
19% (9%) and 11% (1%) respectively. |
|
Aurobindo’s thrust into regulated
markets and formulation business has contributed
to the improved performance. |
|
The formulations sales have grown
by 258% and now constitute 28% total sales. The
contribution of SSPs, Cephalosporins, Antivirals
& other APIs to total sales now stand at 23%,
30% and 19% respectively reflecting a decisive
improvement in the dosage formulations business. |
|
Export sales have grown by 86%
and constitute 58% (47%) of total sales. The
exports have shown significant improvement
across all markets. The contribution of
Americas, Europe & Africa/CIS/Asia to the total
exports now stand at 27%, 27% & 46%
respectively. |
|
During the quarter Aurobindo has
acquired a USFDA compliant cGMP facility in
Dayton, New Jersey, USA. |
|
The formulations facility
situated at Bachupally Village (Unit III) is
converted to 100% EOU with effect from July 1,
2006. |
Further ramping up of filings in
Q2 FY07
During the quarter 9 ANDAS and 14 DMFs are filed
in US alone. In addition to USA, Aurobindo
ramped up the filings in other key regulated
markets like Europe. MCC South Africa has
inspected and approved Unit XII, Hyderabad,
Andhra Pradesh. Aurobindo’s approvals are
studded with two tentative NDA approvals from US
FDA and two (inclusive of tentative) ANDA
approvals. In addition, the Company has
received four ARV approvals from MCC South
Africa and one product was approved by UKMHRA. |
|
During the quarter Aurobindo has
entered into license agreement with M/s. Gilead
Sciences to manufacture and sell their latest
ARV Tenofovir. The Company has also received
accolades for its innovative and utility
oriented packing in receiving India Star award
for Packaging Excellence. |
|
The Chairman of the company was
amongst the select few to be honoured at UN Hqrs
by Mr. Kofi Annan for its initiative to
make the ARVs affordable in the African markets. |
|
The Compensation Committee has
granted Options to Employees under Employees
Stock Option Plan – 2006. The said Plan was
approved by the shareholders on September 18,
2006 at the Annual General Meeting of the
Company. The Board of Directors also noted the
same in their meeting held today. |
|
Snapshot of filings: |
| |
Q2 FY07 |
Cumulative as on
30th Sept.2006 |
|
ANDAs/USA |
9 |
69 |
|
DMFs/USA |
14 |
93 |
|
Formulation dossiers in
Europe, South Africa & Canada |
22 |
106 |
|
API dossiers in Europe &
Canada |
52 |
189 |
|
Patents |
19 |
216 |
|
|
DMFs /ANDAs /formulation
dossiers filed across globe. |
1267 |
|
|
Financial Snapshot: |
|
Rs. Mio |
|
Cumulative as on 30th
Sept 2006 |
| |
Q2 FY07 |
% Growth |
|
Total income |
5067 |
55 |
|
EBIDTA |
958 |
229 |
|
PBT |
606 |
2324 |
|
PAT |
546 |
1417 |
|
EBIDTA |
19 % |
9% (Q1 06) |
|
PAT |
11% |
1% (Q1 06) |
|
|
Sales Snapshot: |
|
Growth across segments |
Rs. Mio |
|
|
Markets |
Size |
Growth (Q2 O Q2) % |
|
India |
1998 |
18 |
|
Americas |
761 |
70 |
|
Europe |
762 |
228 |
|
Africa, Asia |
1279 |
55 |
|
|
Product Mix |
Growth (Q2 O Q2) % |
% |
|
APIs |
23 |
72 |
|
Formulations |
258 |
28 |
|
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company’s robust
product portfolio is spread over 6 major
therapeutic/product areas encompassing
(Antibiotics, Anti-Retrovirals, CVS/ Statins/Diabetology,
CNS, Gastro/Uro/Kidney therapeutics, Anti
fungal/ allergics/respiratory) around 65
Betalactam APIs and 123 Non-Betalactam APIs.
The Company markets its products
in over 100 countries. The company has filed
over 65 ANDAs and 88 DMFs for the USA market, in
addition to several filings in other countries.
The company has received approvals for several
facilities from leading regulatory agencies like
US FDA, UK MHRA, WHO, Health Canada, MCC South
Africa. |
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 5572 5000
Email : ir@aurobindo.com |
|
|
|
|
PRESS
ROOM
